A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome

Jensterle, Mojca; Kravos, Nika Aleksandra; Pfeifer, Marija; Kocjan, Tomaž; Janež, Andrej

doi:10.1007/bf03401383

Cited by 77 publications

(99 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The efficacy of liraglutide was evaluated in another trial of 84 overweight or obese women who had a diagnosis of PCOS [28]. In this 12 week trial, 32 obese women with newly diagnosed PCOS were randomized to receive metformin 1000 mg twice daily or liraglutide 1.2 mg daily.…”

Section: Clinical Trialsmentioning

confidence: 99%

Liraglutide (Saxenda<sup>®</sup>) as a Treatment for Obesity

Onge¹,

Miller²,

Motycka³

2016

FNS

View full text Add to dashboard Cite

Obesity is a significant concern in the United States, affecting approximately 35% of the population. Comorbidities, such as diabetes, hypertension, and hyperlipidemia, significantly increase one's risk of heart attack, stroke, and even death. Liraglutide, a medication originally used to treat diabetes, has been approved for the treatment of obesity. Clinical trials have shown significant improvements in body weight and body mass index (BMI) at a dose of up to 3.0 mg daily. The most common adverse effects are gastrointestinal in nature, however, these often subside with time. Safety concerns with regards to thyroid tumors and pancreatitis should be carefully considered prior to use of this agent. Liraglutide should be considered an additional tool in the treatment of obesity, especially in patients with concomitant diabetes.

show abstract

Section: Clinical Trialsmentioning

confidence: 99%

Liraglutide (Saxenda<sup>®</sup>) as a Treatment for Obesity

Onge¹,

Miller²,

Motycka³

2016

FNS

View full text Add to dashboard Cite

show abstract

“…The reported mean weight losses were 6.5 kg with liraglutide plus metformin, 3.8 kg with liraglutide alone and 1.2 kg with metformin alone [13] . Furthermore, short-term treatment with liraglutide was associated with significantly greater weight loss in a subset of obese patients with newly diagnosed PCOS and higher metabolic risk profile when compared to metformin and lifestyle intervention [14] . Both study designs were conducted with low dose liraglutide 1.2 mg before high dose liraglutide 3 mg was approved as an anti-obesity drug.…”

Section: Potential New Pharmacological Approaches In Obese Women Withmentioning

confidence: 96%

Potential New Pharmacological Approaches in Obese Women with Polycystic Ovary Syndrome

Jensterle¹,

Internationals²

2017

JDO

Self Cite

View full text Add to dashboard Cite

Obesity is frequently present in women with polycystic ovary syndrome (PCOS). It aggravates the adverse features of the syndrome and increases the metabolic risk in this population. Weight management by life style intervention often remains unsatisfactory and non-sustainable. In the present mini review, we revised limited studies addressing the potential use of agents mediating through glucagon-like peptide (GLP)-1 in PCOS. We reported that short-term intervention with long acting GLP-1 analogue liraglutide is associated with consistent BMI decrease in treatment naive obese women with PCOS and in those who had been previously poor responders to metformin and life style modification. Metformin, a well-established therapy used in PCOS with high metabolic risk, was recognized as a mechanistically well-suited combination with liraglutide. Short-term intervention with liraglutide also improved eating behavior in obese PCOS. Furthermore, we discussed the potential association of genetic variability of GLP-1 receptor and inter-individual differences in response to liraglutide regarding weight reduction. In addition, we challenged the original concept related to the enhancement of GLP-1 mediated action through phosphordiesterase 4 (PDE 4) inhibitions as a new potential therapeutic target in obesity-related population. We concluded that GLP-1 mediated agents are promising treatment strategies in the management of obese PCOS. However, larger sample size studies with longer durations of treatment may be required to examine potential benefits of these medications in decreasing metabolic risk and improving reproductive out come in obese PCOS.

show abstract

“…It has also been reported that a GLP-1R agonist improved steatohepatitis in a murine NASH model by regulating hepatic fatty acid metabolism 49) . In addition, treatment with a GLP-1R agonist decreased weight gain in obese mice by activating fat metabolism 50) , and in obese women, it reduced the body mass index (BMI) 51) . Furthermore, a GLP-1R agonist reduced serum concentrations of TNF-, IL-1 , IL-6, and soluble CD163, all of which are known macrophagederived inflammatory molecules in patients with type 2 diabetes mellitus 52) .…”

Section: Glucagon-like Peptide-1 Agonist and Oncostatin M May Be Usefmentioning

confidence: 99%

Contribution of Macrophage Polarization to Metabolic Diseases

Komohara

Fujiwara

Ohnishi

et al. 2016

J Atheroscler Thromb

View full text Add to dashboard Cite

Macrophage activation is one of the major immunological events in the pathogenesis of various diseases. Recent studies have disclosed that complicated mechanisms are involved in macrophage activation and polarization, and many published research articles have been based on the M1/M2 polarization concept. It is considered that M1-and M2-like macrophages are associated with T helper (Th)1-type and Th2-type immune responses, respectively, via several immune mediators. In this article, we summarize the correlations between macrophage polarization and metabolic disorders in both humans and mice and discuss the contribution of macrophage polarization to the pathogenic process of metabolic diseases.J Atheroscler Thromb, 2016; 23: 10-17.

show abstract

A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome

Cited by 77 publications

References 31 publications

Liraglutide (Saxenda<sup>®</sup>) as a Treatment for Obesity

Liraglutide (Saxenda<sup>®</sup>) as a Treatment for Obesity

Potential New Pharmacological Approaches in Obese Women with Polycystic Ovary Syndrome

Contribution of Macrophage Polarization to Metabolic Diseases

Contact Info

Product

Resources

About

A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome

Cited by 77 publications

References 31 publications

Liraglutide (Saxenda&lt;sup&gt;&#174;&lt;/sup&gt;) as a Treatment for Obesity

Liraglutide (Saxenda&lt;sup&gt;&#174;&lt;/sup&gt;) as a Treatment for Obesity

Potential New Pharmacological Approaches in Obese Women with Polycystic Ovary Syndrome

Contribution of Macrophage Polarization to Metabolic Diseases

Contact Info

Product

Resources

About

Liraglutide (Saxenda<sup>®</sup>) as a Treatment for Obesity

Liraglutide (Saxenda<sup>®</sup>) as a Treatment for Obesity